RT Journal Article
SR Electronic
T1 SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.30.21264363
DO 10.1101/2021.09.30.21264363
A1 Anderson, Elizabeth M.
A1 Eilola, Theresa
A1 Goodwin, Eileen
A1 Bolton, Marcus J.
A1 Gouma, Sigrid
A1 Goel, Rishi R.
A1 Painter, Mark M.
A1 Apostolidis, Sokratis A.
A1 Mathew, Divij
A1 Dunbar, Debora
A1 Fiore, Danielle
A1 Brock, Amanda
A1 Weaver, JoEllen
A1 Millar, John S.
A1 DerOhannessian, Stephanie
A1 ,
A1 Greenplate, Allison R.
A1 Frank, Ian
A1 Rader, Daniel J.
A1 Wherry, E. John
A1 Hensley, Scott E.
YR 2021
UL http://medrxiv.org/content/early/2021/10/01/2021.09.30.21264363.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines elicit higher levels of antibodies compared to natural SARS-CoV-2 infections in most individuals; however, the specificities of antibodies elicited by vaccination versus infection remain incompletely understood. Here, we characterized the magnitude and specificity of SARS-CoV-2 spike-reactive antibodies from 10 acutely infected health care workers and 23 participants who received mRNA-based SARS-CoV-2 vaccines. We found that infection and primary mRNA vaccination elicited S1 and S2-reactive antibodies, while secondary vaccination boosted mostly S1 antibodies. Using magnetic bead-based absorption assays, we found that SARS-CoV-2 infections elicited a large proportion of original antigenic sin-like antibodies that bound efficiently to common seasonal human coronaviruses but poorly to SARS-CoV-2. In converse, vaccination only modestly boosted antibodies reactive to common seasonal human coronaviruses and these antibodies bound efficiently to SARS-CoV-2. Our data indicate that SARS-CoV-2 mRNA vaccinations elicit fundamentally different antibody responses compared to SARS-CoV-2 infections.HIGHLIGHTSSARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to SARS-CoV-2 infectionsThe first dose of an mRNA vaccine generates both S1 and S2 responses while the second dose boosts primarily S1-specific antibodiesSARS-CoV-2 infections, but not mRNA vaccinations, elicit high levels of antibodies that bind strongly to seasonal coronaviruses but weakly to SARS-CoV-2Competing Interest StatementE.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (U.S. patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. S.E.H. has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report.Clinical Trialn/a, study was completed with de-identified samples from a separate studyFunding StatementThis project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00015. This work was supported in part by institutional funds from the University of Pennsylvania and NIH U19AI082630 (S.E.H. and E.J.W.). E.M.A. was supported by the NIH Training in Virology T32 Program (T32-AI-007324). We thank J. Lurie, J. Embiid, J. Harris, and D. Blitzer for philanthropic support. We thank all members of the Penn COVID-19 Sample Processing Unit. We would like to thank David Anderson for assistance with the graphical abstract. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were collected after obtaining informed consent and studies were approved by the University of Pennsylvania Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript.